ARCC-4

• UNSPSC Description:

  ARCC-4 is a low-nanomolar Androgen Receptor (AR) degrader based on PROTAC, with a DC50 of 5?nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1].

• Target Antigen:

  Androgen Receptor; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/arcc-4.html

• Purity:

  99.88

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  O=C(NCC1=CC=C(C2=C(C)N=CS2)C=C1)[C@H]3N(C([C@H](C(C)(C)C)NC(COCCCCOC4=CC=C(C5=CC=C(N(C(N6C7=CC=C(C#N)C(C(F)(F)F)=C7)=S)C(C)(C)C6=O)C=C5)C=C4)=O)=O)C[C@H](O)C3

• Molecular Weight:

  1024.18

• References & Citations:

  [1]Salami J, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1973403-00-7